Peter Homa CBE to chair collaboration partnership board

Peter HomaPeter Homa CBE, former chief executive of Nottingham University Hospitals NHS Trust and current chair of the NHS Leadership Academy, has been appointed independent chair of the Partnership Board for the collaboration between Royal Brompton & Harefield NHS Foundation Trust and King’s Health Partners. 

In November, plans were announced to create a global powerhouse for heart and lung medicine and research in London, bringing together the specialist skills and expertise from Royal Brompton & Harefield, Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts and King’s College London.

The scale and range of services offered by the collaboration would benefit patients on a regional, national and international level, directly reaching a diverse population of more than 12 million people.

The Partnership Board is accountable to the partner Trust Boards and College Council and will set the strategic direction as the collaboration
develops its plans over the coming months.

Peter Homa has a wealth of front line knowledge and leadership experience having spent 27 years as a chief executive, at local and national level. He was chief executive of the Healthcare Commission between 1999 and 2003 and chief executive of St George’s NHS Trust between 2003 and 2006.

In addition to chairing Partnership Board meetings, Peter will work alongside the partners to raise awareness of the wider benefits of the collaboration, particularly in supporting the UK life sciences’ and medical technologies industries.

He will also seek to promote new research & educational opportunities with the collaboration’s existing academic partners, Imperial College London and King’s College London, identifying any areas where the combined resources of both universities can make a significant contribution.

Commenting, Peter Homa said: “I was delighted to be asked to take on this role. This is an unprecedented opportunity to bring together organisations that lead in the treatment and research of cardiovascular and respiratory conditions, with strong international reputations. I look forward to playing my part in making the vision a reality.”

Share